Buy Reblozyl (luspatercept)

What is Reblozyl (luspatercept) for?

Buy Reblozyl (luspatercept). Reblozyl (luspatercept) is a treatment for low red blood cells in adults. It helps those with:

• transfusion-dependent anemia (low red blood cells) linked to beta thalassemia.
• myelodysplastic syndromes with ring sideroblasts (MDS‑RS) or myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN‑RS‑T) who need regular RBC transfusions and have not responded well to or cannot receive an erythropoiesis stimulating agent (ESA).

It’s not meant to replace red blood cell transfusions for immediate anemia treatment.

It comes in vial form for injections under the skin.

How does Reblozyl (luspatercept) work?

Beta thalassemia is a genetic blood disease. It causes less healthy red blood cells, leading to severe anemia. Myelodysplastic syndromes (MDS) are blood cancers that also lead to anemia due to poor RBC production.

Those needing regular blood transfusions face risks like iron overload and infections.

Luspatercept helps immature RBCs mature. This increases the number of healthy RBCs in the blood, improving anemia.

Where has Reblozyl (luspatercept) been approved?

Reblozyl (luspatercept) has been approved by:

• The Food and Drug Administration (FDA), USA for the treatment of:
  • anemia in adults with beta thalassemia on November 8, 2019.
  • myelodysplastic syndromes (MDS) on April 3, 2020.
• The European Medicines Agency (EMA), for the treatment of:
  • anemia in adults with beta thalassemia on June 26, 2020.
  • myelodysplastic syndromes (MDS) on June 26, 2020.
• Health Canada for the treatment of adults with beta thalassemia on September 29, 2020

It’s the first in its class, helping patients reduce their need for blood transfusions.

This medicine may also be approved in other regions. If you have questions, contact our support team.

 

How is Reblozyl (luspatercept) taken?

The standard dosage is:

• 1 mg/kg body weight once every 3 weeks by injection under the skin (subcutaneous).

Your doctor will check your hemoglobin levels before each dose. They may adjust the dose or schedule based on these results.

If a dose is missed, it should be given as soon as possible. This ensures treatment continues with at least 3 weeks between doses.

Continue taking Reblozyl (luspatercept) as long as it works for you and you can handle any side effects.

For full details on dosage and administration, see the official prescribing information in our references section.

Note: Please consult with your treating doctor for personalized dosing.

Are there any known adverse reactions or side effects of Reblozyl (luspatercept)?

Common adverse reactions

The most common side effects (≥20% of patients) include:

• Tiredness
• Muscle or bone pain
• dizziness
• Diarrhea
• Stomach (abdominal) pain
• Allergic reactions
• Headache
• Joint pain (arthralgia)
• Nausea
• Cough
• Trouble breathing

Serious adverse reactions

The serious side effects listed are:

• Blood clots in the arteries, veins, brain, and lungs
• High blood pressure

Use in a specific population

Reblozyl  luspatercept) may affect fertility in women. It can also harm a fetus if a pregnant woman takes it. It’s best to avoid pregnancy and breastfeeding.

For a full list of side effects and adverse reactions, see the official prescribing information.

Buy Oxbryta (voxelotor)